Zosano Pharma is a clinical-stage biopharmaceutical company enabling the systemic administration of therapeutics and other bioactive molecules to patients using our proprietary intracutaneous microneedle patch system. We have pioneered a novel paradigm for delivering molecules typically administered parenterally, where the inconvenience and pain associated with subcutaneous, intravenous or other complex administrations present barriers to compliance. Our strengths lie in our diverse team of industry veterans with proven drug and device development and significant commercialization experience.
With our proprietary intracutaneous microneedle patch system, therapeutic blood levels are obtained more rapidly than with oral administration.
Ready. Set. Apply. Three easy steps for administration.
October 4,
2021
Zosano Pharma Granted Type C Meeting with FDA Regarding NDA Resubmission for M207 Following Preliminary Top-Line Pharmacokinetic Study Results
September 2,
2021
Zosano Pharma to Present at the H.C. Wainwright Virtual Global Investment Conference
August 10,
2021
Zosano Pharma Reports Second Quarter 2021 Financial Results
*M207 (zolmitriptan intracutaneous microneedle system)